Logo
Asia Pacific Autoimmune Disease Diagnostics Market 2021-2031

Asia Pacific Autoimmune Disease Diagnostics Market 2021-2031

Bonafide Trust 02-02-2022 131 Pages
Region : Asia-Pacific Category : Lifescience Medical Devices

Asia Pacific autoimmune disease diagnostics market will grow by 9.7% annually with a total addressable market cap of $19.06 billion over 2022-2031 owing to the growing prevalence of autoimmune diseases, the strong investment in research and development activities, the rise in technological advancements, increasing patient awareness and healthcare expenditure, and favorable government policies. Highlighted with 35 tables and 70 figures, this 131-page report “Asia Pacific Autoimmune Disease Diagnostics Market 2021-2031 by Product (Assay Kits & Consumables, Analyzers & Instruments), Test Type (Autoantibodies and Immunologic, Inflammatory Marker, Routine Laboratory, Others), Disease Type (Systemic, Localized), Gender (Female, Male), Age (<44, 44-64, >64), End User (Hospitals, Clinics, Diagnostic Labs), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific autoimmune disease diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific autoimmune disease diagnostics market in every aspect of the classification from perspectives of Product, Test Type, Disease Type, Gender, Age, End User, and Country. Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Assay Kits & Consumables • Analyzers & Instruments Based on Test Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Autoantibodies and Immunologic Tests • Antinuclear Antibody Tests • Anti-cyclic Citrullinated Peptide • Enzyme-Linked Immunosorbent Assay (ELISA) • Rheumatoid Factor • Thyroid Antibody Tests • Other Autoantibodies and Immunologic Tests • Inflammatory Marker Tests • C-Reactive Protein (CRP) • Erythrocyte Sedimentation Rate (ESR) • Other Inflammatory Marker Tests • Routine Laboratory Tests • Urinalysis • Complete Blood Count (CBC) Tests • Other Routine Laboratory Tests • Other Test Types Based on Disease Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Systemic Autoimmune Disease • Rheumatoid Arthritis • Systemic Lupus Erythematosus (SLE) • Psoriasis/Psoriatic Arthritis • Other Systemic Autoimmune Diseases • Localized Autoimmune Disease • Thyroiditis • Multiple Sclerosis • Inflammatory Bowel Disease • Type 1 Diabetes • Other Localized Autoimmune Diseases Based on Gender, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Female Patients • Male Patients Based on Age, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • < 44 • 44 - 64 • > 64 Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Hospitals • Clinics • Diagnostic Labs • Other End Users Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of the regional market by country and split of key national markets by Product, Disease Type, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Abbott Laboratories Beckman Coulter, Inc. Biomerieux SA Bio-rad Laboratories Inc. F. Hoffmann-la Roche Ltd. Hemagen Diagnostics Inc. Myriad Genetics Inc. PerkinElmer Inc. (Euroimmun AG) Quest Diagnostics Inc. Siemens Healthineers Inc. Thermo Fisher Scientific Inc. Trinity Biotech PLC Werfen Company (Inova Diagnostics Inc.) (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Read More

Card image cap

Interested in this report?
Get your FREE sample!

Requirement Gathering & Methodology
Data Collection Techniques
Our Research Team & Data Sourcing
Data Science & Analytical Tools
Data Visualization & Presentation Skills
Project/ Report Delivery & After Sales Services